Clozapine: Balancing safety with superior antipsychotic efficacy

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 3, 2012, Pages 134-144

  Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Agranulocytosis; Clozapine; Metabolic side effects; Myocarditis; Schizophrenia; Suicide; Treatment resistant

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AGRANULOCYTOSIS; CARDIOVASCULAR RISK; COGNITION; DELUSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HALLUCINATION; HUMAN; METABOLIC DISORDER; MORTALITY; MYOCARDITIS; NONHUMAN; REVIEW; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE; TARDIVE DYSKINESIA;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; METABOLIC DISEASES; MYOCARDITIS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84867338300     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.6.3.5     Document Type: Review

References (93)

1. Horvitz-Lennon M, Donohue JM, Domino ME, Normand SL. Improving quality and diffusing best practices: the case of schizophrenia. Health Aff (Millwood) 2009;28(3):701-712.
2. Healy D. The creation of psychopharmacology. Cambridge (MA); Harvard University Press: 2004.
3. Tang YL, Mao PX, Jiang F, Chen Q, Wang CY, Cai ZJ, et al. Clozapine in China. Pharmacopsychiatry 2008;41(1):1-9. (Pubitemid 351195886)
4. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I. Clozapine and agranulocytosis. Lancet 1975;2(7935):611.
5. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11(3):193-198. (Pubitemid 8072136)
6. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 1977;56(4):241-248. (Pubitemid 8190606)
7. Ekblom B, Eriksson K, Lindström LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 1984;83(3):293-294. (Pubitemid 14083656)
8. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology (Berl) 1978;56(1):75-80. (Pubitemid 8270659)
9. Meltzer HY, Luchins DJ. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 1984;4(5):286-287. (Pubitemid 14013152)
10. Singer JM. Clozapine and tardive dyskinesia. Arch Gen Psychiatry 1983;40(3):347-348. (Pubitemid 13161609)
11. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-796.
12. Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997;14(1):1-20. (Pubitemid 28080714)
13. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
14. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-1762. (Pubitemid 350247505)
15. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. Schizophr Bull 2004;30(2):193-217.
16. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156(4):544-549. (Pubitemid 29162974)
17. Meltzer HY, Lee M, Cola P. The evolution of treatment resistance: biological implications. J Clin Psychopharmacology 1998;18:5S-11S. (Pubitemid 28191580)
18. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 1998;18(2 Suppl 1):20S-24S. (Pubitemid 28191582)
19. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152(2):183-190.
20. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34(10):702-712. (Pubitemid 23354783)
21. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235(1):60-64.
22. Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001;62(Suppl 23):39-44. (Pubitemid 32952693)
23. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11):1686-1696. (Pubitemid 29517559)
24. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354(9193):1841-1845.
25. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345(3):224-225. (Pubitemid 32662140)
26. Kane JM, Woerner M, Lieberman J. Epidemiological aspects of tardive dyskinesia. Encephale 1988;14 Spec No:191-194.
27. Lee MA, Thompson P, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55:82-87. (Pubitemid 24353024)
28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223. (Pubitemid 41345943)
29. Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010;177(3):286-293.
30. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151(10):1409-1416. (Pubitemid 24301683)
31. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009;(1):CD000059.
32. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32(4):715-723. (Pubitemid 44412859)
33. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69(2):274-285. (Pubitemid 351469271)
34. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; INITIATE Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009;110(1-3):80-89.
35. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-760. (Pubitemid 28252653)
36. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156(2):294-298. (Pubitemid 29077121)
37. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159(2):255-262. (Pubitemid 34126903)
38. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610. (Pubitemid 44464569)
39. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-246.
40. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50(9):329-338. (Pubitemid 19239055)
41. Joffe G, Venäläinen E, Tupala J, Hiltunen O, Wahlbeck K, Gädeke R, et al. The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in out-patients. Int Clin Psychopharmacol 1996;11(4):265-272. (Pubitemid 27049291)
42. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17(2):247-261.
43. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152(6):827-832.
44. Meltzer HY. Suicide in schizophrenia, clozapine and adoption of evidence-based medicine. J Clin Psychiatry 2005;66:530-533. (Pubitemid 40593583)
45. Asnis GM, Friedman TA, Sanderson WC, Kaplan ML, van Praag HM, Harkavy-Friedman JM. Suicidal behaviors in adult psychiatric outpatients, I: Description and prevalence. Am J Psychiatry 1993;150(1):108-112. (Pubitemid 23059173)
46. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005;62(3):247-253. (Pubitemid 40990969)
47. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8(6):671-677. (Pubitemid 27449500)
48. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior. J Clin Psychiatry 2005;66(4):534-538.
49. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al.; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82-91 (Pubitemid 36070868)
50. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374(9690):620-627.
51. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010;117(1):68-74.
52. Meltzer HY, McGurk SR. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255. (Pubitemid 29272503)
53. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999;60(Suppl 12):24-29. (Pubitemid 29283179)
54. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharm 2005;8:457-472. (Pubitemid 41002500)
55. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010;35(5):1053-1062.
56. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al.; for the CATIE investigators and the neurocognitive working group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-647. (Pubitemid 46878665)
57. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharm Exp Thera 2010;332(2):622-631.
58. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990;41:892-897. (Pubitemid 20315479)
59. Meltzer, HY. Quality of life in schizophrenia: importance for psychopharmacology research and practice. Quality of Life Newsletter 1994;9:8-9.
60. Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Suárez D, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009;12(4):536-543.
61. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337(12):809-815. (Pubitemid 27391630)
62. Lindström LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77(5):524-529.
63. Meltzer HY, Alphs LD, Bastani B, Ramirez LF, Kwon K. Clinical efficacy of clozapine in the treatment of schizophrenia. Pharmacopsychiatry 1991;24(2):44-45.
64. Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci 1999;11(4):481-489.
65. Kaneda Y, Jayathilak K, Meltzer HY. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. Psychiatry Res 2009;169(2):178-179.
66. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156(7):990-999. (Pubitemid 29302789)
67. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow up. BMJ 2006;333(7561):224-227. (Pubitemid 44406713)
68. Ahn YM, Chang JS, Kim Y, Lee KY, Kim JH, Kim SC, et al. Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment. Int Clin Psychopharmacol 2005;20(3):157-161. (Pubitemid 40571514)
69. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156(6):863-868. (Pubitemid 29260340)
70. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(Suppl 3):3-7. (Pubitemid 28196363)
71. Schulte PF. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40(4):683-688.
72. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007;33(5):1221-1224. (Pubitemid 47347911)
73. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11(1):25-32. (Pubitemid 32162499)
74. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70(1):1-17. (Pubitemid 38916622)
75. Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35(11):1381-1387. (Pubitemid 33042072)
76. Lund BC, Perry PJ, Brooks JM, Arndt S. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58(12):1172-1176.
77. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149(1):68-72.
78. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003;59:19-27. (Pubitemid 35291087)
79. Meltzer HY, Lee MA, Ranjan R, Mason ED, Cola PA. Relapse following clozapine withdrawal: effect of cyproheptadine plus neuroleptic. Psychopharmacology 1996;124:176-187. (Pubitemid 26111438)
80. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14- week, double-blind, parallel-group, placebocontrolled study. Schizophr Res 2009;113(1):19-26.
81. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009;29(1):16-20.
82. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714. (Pubitemid 43175488)
83. Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19(7):415-422. (Pubitemid 39422495)
84. Li CR, Chung YC, Park TW, Yang JC, Kim KW, Lee KH, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry 2009;10(4 Pt 3):919-924.
85. Miller DD, Sharafuddin MJ, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991;52(3):99-101.
86. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003;26(9):643-659. (Pubitemid 36871837)
87. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48(7):263-267. (Pubitemid 17108402)
88. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005;25(1):32-41. (Pubitemid 40129380)
89. Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002;21(4):189-203. (Pubitemid 36018766)
90. Yaǧcioǧlu AEA, Akdede BBK, Turgut TI, Tümü klü M, Kâzim Y, Alptekin K, et al. A double-blind controlled study adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
91. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010;35(11):2274-2283.
92. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9(5):410-418. (Pubitemid 352025195)
93. Cormac I, Brown A, Creasey S, Ferriter M, Huckstep B. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand 2010;121(5):393-397.